Results 41 to 50 of about 19,019 (189)

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis

Frontiers in Pharmacology, 2021
Introduction: The extensive utilisation of antiretroviral therapy has greatly improved the survival rates of those infected with human immunodeficiency virus (HIV).
Ke Zhang, Ke Zhang, Yang Zhang, Yang Zhang, Xinchao Liu, Aixin Li, Meixia Gao, Jianhua Hou, Jianhua Hou, Chunxiang Guo, Tong Zhang, Tong Zhang, Hao Wu, Hao Wu, Guanzhi Chen, Xiaojie Huang   +15 more
doaj   +1 more source

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases, 2010
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj  

Dolutegravir-Associated Hyperglycemia in a Patient on Highly Active Antiretroviral Therapies

Nigerian Journal of Medicine
Highly active antiretroviral medications have been reported to cause hyperglycaemia in the literature especially the protease inhibitor. We however report a case of dolutegravir-associated hyperglycaemia which is an integrase strand transfer inhibitor.
Abosede Grace Adeyeye, Victor Oladeji Adeyeye   +1 more
doaj   +1 more source

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth

Nature Communications, 2022
Neonates and infants infected with HIV generally develop disease rapidly, with early antiretroviral therapy (ART) often failing to achieve a sustained state of ART-free virologic remission.
Xiaolei Wang, Eunice Vincent, Summer Siddiqui, Katherine Turnbull, Hong Lu, Robert Blair, Xueling Wu, Meagan Watkins, Widade Ziani, Jiasheng Shao, Lara A. Doyle-Meyers, Kasi E. Russell-Lodrigue, Rudolf P. Bohm, Ronald S. Veazey, Huanbin Xu   +14 more
doaj   +1 more source

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

Retrovirology, 2008
HIV-1 integrase is the third enzymatic target of antiretroviral (ARV) therapy. However, few data have been published on the distribution of naturally occurring amino acid variation in this enzyme.
Gifford Robert J, Zioni Rafael, Kiuchi Mark, Liu Tommy F, Rhee Soo-Yon, Holmes Susan P, Shafer Robert W   +6 more
doaj   +1 more source

Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors

Molecules, 2010
In spite of significant progress in anti-HIV-1 therapy, current antiviral chemo-therapy still suffers from deleterious side effects and emerging drug resistance.
Didier Desmaële, Jean-François Mouscadet   +1 more
doaj   +1 more source

Potential benefit of dolutegravir once daily: efficacy and safety

HIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj  

EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN

Pakistan Armed Forces Medical Journal, 2021
Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced patients, their management and outcome. Study Design: Cross sectional study. Place and Duration of Study: Ruth KM Pfau Civil Hospital, Karachi Pakistan, from
Farzana Batool, Sohaima Manzoor, Azizullah Khan Dhiloo, Humera Muhammad Ismail, Shah Muhammad Shaikh, Shehla Baqi   +5 more
doaj